Verici Dx’s name (probably) derives from combining the words “verity” (truth) and “diagnostics” – together meaning the “truth in medical testing.”
Similarly, having the best technology, certainly makes it easier for an early stage business (like hashtag#VRCI) to open industry doors, punch above its weight and ultimately disrupt a highly regulated, yet very profitable $700m life sciences market.
Encouraging too today, the company said that the commercialisation of its flagship blood test Tutivia for post transplant, acute kidney rejection, was accelerating.
Reporting in Q3’25, a 19% sequential jump in clinicians using the product - alongside the addition of 9 new transplant centres, taking the total to 30 across the US, representing 16% of annual transplants (vs 10% in June).
The benefits of which are anticipated to flow through in increased volumes from Q4 onwards, with Q3'25 orders being consistent with the previous 2 (ie circa 300/qrt).
Elsewhere Verici Dx has also expanded its commercial team with 2 new senior sales hires, with a Director of Clinical Partnerships set to join as well in mid-October.
In term of the numbers, “the Board continues to target meeting market expectations for the full year”. Where Singer Capital Markets have a 2.9p/share target price, underpinned by FY'25 revenues of $4.2m (vs $3.3m LY) and adjusted LBITDA of -$5.9m - closing Dec'25 with net cash of $2.6m.